- Home
- EQS vs BIAF Comparison
EQS vs BIAF Comparison
Compare EQS & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQS
- BIAF
- Stock Information
- Founded
- EQS 1991
- BIAF 2014
- Country
- EQS United States
- BIAF United States
- Employees
- EQS N/A
- BIAF N/A
- Industry
- EQS Finance Companies
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- EQS Finance
- BIAF Health Care
- Exchange
- EQS Nasdaq
- BIAF Nasdaq
- Market Cap
- EQS 18.5M
- BIAF 21.4M
- IPO Year
- EQS N/A
- BIAF 2022
- Fundamental
- Price
- EQS $1.18
- BIAF $1.24
- Analyst Decision
- EQS
- BIAF Strong Buy
- Analyst Count
- EQS 0
- BIAF 1
- Target Price
- EQS N/A
- BIAF $6.00
- AVG Volume (30 Days)
- EQS 3.4K
- BIAF 102.5K
- Earning Date
- EQS 01-01-0001
- BIAF 11-14-2024
- Dividend Yield
- EQS N/A
- BIAF N/A
- EPS Growth
- EQS N/A
- BIAF N/A
- EPS
- EQS N/A
- BIAF N/A
- Revenue
- EQS $1,137,000.00
- BIAF $9,367,785.00
- Revenue This Year
- EQS N/A
- BIAF $302.41
- Revenue Next Year
- EQS N/A
- BIAF $15.00
- P/E Ratio
- EQS N/A
- BIAF N/A
- Revenue Growth
- EQS 1795.00
- BIAF 2813.87
- 52 Week Low
- EQS $1.17
- BIAF $1.20
- 52 Week High
- EQS $1.95
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- EQS 37.54
- BIAF 35.39
- Support Level
- EQS $1.17
- BIAF $1.21
- Resistance Level
- EQS $1.25
- BIAF $1.37
- Average True Range (ATR)
- EQS 0.05
- BIAF 0.08
- MACD
- EQS -0.01
- BIAF 0.01
- Stochastic Oscillator
- EQS 4.00
- BIAF 5.00
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invest primarily in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts and recapitalizations of existing businesses or special situations and achieve capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.